期刊文献+

新疆维族与汉族前列腺疾病患者PSA系列水平的差异性研究 被引量:1

Differences of PSA series in patients with Prostatic disease between Uygurs and Han nationality of Xinjiang District
暂未订购
导出
摘要 目的探讨新疆维族与汉族前列腺疾病患者PSA系列水平的差异性。方法采用微粒子免疫荧光捕获法检测维族与汉族前列腺疾病患者血清fPSA和tPSA水平及其比值。结果分析显示维族与汉族患者fPSA和tPSA水平均呈现前列腺癌组>前列腺增生组>慢性前列腺炎组和对照组(FfPSA=92.94,FtPSA=1642,P<0.01;FfPSA=63.67,FtPSA=2074,P<0.01),F/T比值亦均表现为前列腺癌组分别明显低于前列腺增生组、慢性前列腺炎组和对照组(F=8.17,P<0.01;F=12.77,P<0.01)。族别分析显示在前列腺癌组维族与汉族患者tPSA水平呈现统计学显著性差异,汉族患者略高于维族(t=2.16,P<0.05);在前列腺增生组两民族fPSA和tPSA水平间分别存在统计学显著性差异,均表现为汉族患者高于维族(t=7.31,t=20.86,P<0.01)。结论民族间血清PSA系列水平测定无明显的差异性,尤其tPSA与F/T联合监测更有助于维族与汉族患者前列腺疾病的鉴别诊断。 Objective To explore differences of PSA series in patients with Prostatic disease between Uygur and Han nationality of Xinjiang.Methods Microparticle enzyme immunoassay(MEIA) was used to detect serum tPSA and fPSA level and its F/T ratio in Uygur and Han patients with prostatic disease.Results Analysis showed prostate cancerbenign prostate hyperplasiachronic prostatitis and control groups(FtPSA=92.94,FfPSA=1642,P0.01;FtPSA=63.67,FfPSA=2074,P0.01) on tPSA and fPSA level in Uygur and Han patients,and the F/T ratio of prostate cancer group was obviously lower than that of benign prostate hyperplasia、chronic prostatitis and control groups respectively(F=8.17,P0.01;F=12.77,P0.01) in Uygur and Han patients.The difference was found that tPSA level of Han nationality was higher than that of Uygur(t=2.16,P0.05) in prostate cancer groups and tPSA or fPSA of Han was separately higher of Uygur(t=7.31,t=20.86,P0.01).Conclusion The level of serum PSA series demonstrate no obvious differences and especially tPSA and F/T co-detection is helpful to differential diagnosis of Prostatic disease between Uygur and Han patients.
出处 《西部医学》 2012年第2期346-347,349,共3页 Medical Journal of West China
关键词 民族 PSA系列 差异性 Nationality PSA series Difference
  • 相关文献

参考文献8

二级参考文献21

  • 1高中伟.血清PSA的影响因素[J].现代泌尿外科杂志,2001,6(2):60-62. 被引量:9
  • 2Christensson A, Bjork J, Nilsson O,et al. Serum prostate specific antigen complexed to alpha t-antichymorrypsin as an indicator of prostate cancer. J Urol, 1993,150:100-105.
  • 3Jung K, Elgeti U, Lein M, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA:which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clinical Chem, 2000, 46:55-62.
  • 4Bunting P S, DeBoer G, Choo R, et al. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin- Biochem, 2002, 35: 471 -475.
  • 5Khan M A, Carter H B, Epstein J I, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol, 2003, 170:2274-22788.
  • 6Battikhi M N. Age-specific reference ranges for prostate-specific antigen (PSA) in jordanian patients. Prostate-Cancer-Prostatic-Dis, 2003, 6: 256 - 60.
  • 7Jung K,Elgeti U,Lein M,et al.Ratio of free or comlexed prostate-specific antigen to total PSA:which ratio improves differentiation between benign prosatic hyperplasia and prostate cancer[J]?Clinal Chem,2000,46(1):55~62.
  • 8Lein M,Jung K,Elgeti U,et al.Comparison of the clinical validity of free prostate-spcific antigen,alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis[J].Eur Urol,2001,39(1):57~64.
  • 9Jung K,Stephan C,Elgeti U,et al.Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen<4 microg/L:are they useful tools for early detection and screening of prostate cancer[J]?Int J Cancer,2001,93(5):759~765.
  • 10Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med, 1996, 335: 304-310.

共引文献394

同被引文献14

  • 1吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004.589-591.
  • 2Center MM, Jemal A, Lortet- Tieulent J, et al. International variation in prostate cancer incidence and mortality rates [J]. Eur Urol, 2012, 61 : 1079 - 1092.
  • 3Greene KL, Albertsen PC, Babaian R J, et al. Prostate specific antigen best practice statement: 2009 update [J]. Urol, 2009, 182:2232 - 2241.
  • 4Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guide- line for the early detection of prostate cancer: update2010 [J]. CA Can- cer J Clin,2010,60:70 - 98.
  • 5Amir Qaseem MD, Michael J, Barry MD, et al. Screening for prostate cancer: a guidance statement from the clinical Guidelines Committee of the American College of Physicians [J]. Ann Intern Med, 2013, 158: 761 - 769,.
  • 6Schdder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Screening and prostate- cancer mortality in a randomized European study[J]. N Engl J Med,2009,360:1320-1328.
  • 7热依汗.谢依提,杨恺,杨忠礼,买合木提.维族和汉族前列腺癌患者PSA与激素水平的差异性研究[J].临床检验杂志,2008,26(3):214-214. 被引量:3
  • 8华立新,乔迪,宋宁宏,冯宁翰,杨杰,张杰秀,陈建刚,张炜,眭元庚,吴宏飞.应用前列腺特异抗原筛查诊断前列腺癌的临床意义[J].中华肿瘤杂志,2009,31(9):705-709. 被引量:12
  • 9刘明,王建业,朱玲,万钢,赵艳燕,马兰军.中老年男性人群年龄与前列腺特异抗原水平的关系[J].中华老年医学杂志,2010,29(12):999-1001. 被引量:3
  • 10刘建平,梁胜军,王永忠,赵风进,殷振超.PSA对社区老年男性前列腺癌筛查的临床意义和分析[J].广州医学院学报,2010(5):51-53. 被引量:4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部